Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study.

Paolo Andrea ZucaliChia-Chi LinBradley C CarthonTodd M BauerMarcello TucciAntoine ItalianoRoberto IacovelliWu-Chou SuChristophe MassardMansoor SalehGennaro DanieleAlastair GreystokeMartin GutierrezShubham PantYing-Chun ShenMatteo PerrinoRobin MengGiovanni AbbadessaHelen LeeYingwen DongMarielle ChironRui WangLaure LoumagneLucie LépineJohann de Bono

Published in: Journal for immunotherapy of cancer (2022)

NCT03367819.

Keyphrases

open label
clinical trial
phase ii
cancer therapy
phase ii study
phase iii
study protocol
nk cells
randomized controlled trial
drug delivery
radiation therapy
rectal cancer
placebo controlled